Bioavailability of butorphanol after intranasal administration to horses by Ferreira, V. et al.
 
 
Bulgarian Journal of Veterinary Medicine, 2020, 23, No 4, 443447 




BIOAVAILABILITY OF BUTORPHANOL AFTER INTRANASAL 
ADMINISTRATION TO HORSES 
V. FERREIRA, M. I. VELLOSO & M. F. LANDONI 
Cátedra de Farmacología, Facultad de Ciencias Veterinarias, Universidad 
Nacional de La Plata, La Plata, Buenos Aires, Argentina 
Summary 
Ferreira, V., M. I. Velloso & M. F. Landoni, 2020. Bioavailability of butorphanol after in-
tranasal administration to horses. Bulg. J. Vet. Med., 23, No 4, 443447. 
 
The aim of the present study was to describe butorphanol pharmacokinetics and bioavailability fol-
lowing intranasal administration to horses. Six adult horses received 0.05 mg/kg butorphanol, in a 
randomised crossover design, by either intravenous or intranasal route. Plasma concentrations of bu-
torphanol were measured at predetermined time points using liquid chromatography/mass spectrome-
try assay. After intravenous injection, mean ±SD butorphanol steady-state volume of distribution and 
clearance was 3.20 ± 1.77 L/kg and 3.18 ± 1.47 L/kg/h, respectively. Terminal half-lives for butor-
phanol after intravenous and intranasal administrations were 0.68  ±  0.17  h and  1.79 ± 1.43 h. For 
intranasal administration, absorption half-life and peak plasma concentration were 0.43 ± 0.33 h and 
1.95 ± 1.7 ng/mL, respectively. Bioavailability was 54.45 ± 20.09%. Intranasal butorphanol admini-
stration in horses is practical, not stressful and well tolerated. Therefore, it might be a substitute to the 
intravenous route in adult horses. 
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Butorphanol, a synthetic opioid agonist-
antagonist (μ-receptor antagonist and k-
receptor agonist), is commonly used in 
equine medicine and is considered an effi-
cacious and safe visceral analgesic in 
adult horses (Mama & Hector, 2019). It 
causes minimal cardiovascular and respi-
ratory effects and contributes to the mana-
gement of balanced anaesthesia (McFad-
zean & Love, 2018). Butorphanol in hor-
ses is commonly administrated by intrave-
nous route.  
The intranasal route of administration 
is not commonly used in horses. However, 
it is well tolerated (Ferreira et al., 2015) 
and has, in comparison with other admini-
stration routes, a number of advantages  
such as ease of administration and avoid-
ance of first-pass metabolism. 
The objective of the present study was 
to describe the pharmacokinetics and 
evaluate the bioavailability of butorphanol 
after intranasal administration to horses.  
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Six healthy adult Standardbred horses, 
four castrated males and two females, 
were used for this study. Body weight 
ranged from 400 to 547 kg and age from 5 
to 9 years. Horses were housed in box 
stalls and allowed free access to grass hay 
throughout treatment and observation pe-
riods. All experimental protocols were 
approved by the Institutional Animal Care 
and Use Committee, Faculty of Veterinary 
of the National University of La Plata. A 
two-way crossover trial was performed to 
determine the pharmacokinetics and bio-
availability of intranasal (IN) butorphanol 
in horses. Horses were treated with intra-
venous (IV) (n=3) or intranasal (n=3) bu-
torphanol at 0.05 mg⁄kg. After a 2 week 
wash-out period treatments were reversed. 
Prior to administration, a 14G catheter 
was placed in the left jugular vein of each 
horse. A 14G catheter was also placed in 
the right jugular vein for drug administra-
tion in horses receiving intravenous bu-
torphanol. The IV formulation used was a 
commercially available 1% aqueous solu-
tion (Butormin, Holliday-Scott, Argen-
tina). The IN formulation, a 4.16%  aque-
ous solution buffered to a pH value of 4.0 
containing 0.33% sodium citrate, 0.64% 
sodium chloride and 0.64% citric acid, 
provided 8.3 mg of butorphanol tartrate in 
a 0.2-mL spray from a commercially 
available, single-dose metered sprayer 
(Coster Packaging, Argentina). For ad-
ministration, the horses’ heads were ele-
vated for approximately 30 s during the 
administration and for approximately 30 s 
after the administration. No food or water 
was allowed until 4 h or 2 h after admini-
stration, respectively. 
Blood samples were collected from the 
left jugular vein catheter prior to drug 
administration (time 0) and at 2.5, 5, 10, 
15, 20, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 10 and 
12 h after IV or IN administration. Blood 
samples were immediately injected into a 
heparinised glass tube and stored on ice 
until centrifuged for collection of plasma. 
Plasma was stored at  –80 ºC until butor-
phanol concentrations were measured. 
Plasma butorphanol concentrations 
were determined by LC-MS as described 
elsewhere (Knych et al., 2013). The 
method was linear between 0.05 and 50 
ng/mL, intraday and interday variation 
was less than 15 % and LOQ was 0.1 
ng/mL.  
Nonlinear least square regression 
analysis was performed on plasma butor-
phanol concentration vs. time data from 
both treated groups, using commercially 
available software (WinNonlin Version 
5.0, Pharsight, Cary, NC, USA). Only 
data points (plasma concentrations) equal 
to or above the LOQ were included in the 
analysis.  
Pharmacokinetic parameters are re-
ported as mean±SD (Table 1). Main 
pharmacokinetic parameters were statisti-
cally compared for the two administration 
routes, applying Wilcoxon test. Diffe-
rences were considered statistically sig-
nificant when P≤ 0.05. 
No adverse effects were observed in 
any of the experimental animals. Butor-
fanol plasma concentration vs. time curves 
after IV and IN administration were best 
described by an open monoexponential 
model in all the horses (Fig. 1).  
After IV and IN administration, plas-
ma concentrations were maintained above 
the limit of quantification (0.1 ng/mL) 
until the 4th  post-administration hour in 
all the experimental animals. In 5 animals 
concentrations were above LOQ until the 
8th post-administration hour. After intra-
nasal administration, concentrations were 
lower than those observed after intrave-
nous administration. The average peak 
concentration was 1.95±1.75 ng/mL and 
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was presented at 2 hours post-administ-
ration. Inter-subject variability, especially 
in early sample times, was important.   
After intravenous administration, bu-
torphanol was widely distributed, with a 
volume of distribution of 3.20±1.77 L/kg. 
A single experimental animal showed out-
lier type distribution volume. The values 
calculated in the rest of horses (2.06±1.2 
L/kg) were slightly higher than those re-
Table 1.  Mean pharmacokinetic parameters of butorphanol after IV and IN administration to horses 
at a dose rate of 0.05 mg/kg (n=6) 
Intravenous Intranasal  
Mean SD Mean SD 
Actual dose (mg/kg)   0.050   0.000   0.047   0.001 
Kel (L/h)   1.070   0.260   0.514   0.273 
T½ el (h)   0.681   0.169   1.794   1.429 
Kabs (L/h) – –   3.494   3.788 
T½ abs (h) – –   0.426   0.320 
Tmax (h) – –   1.487   0.765 
C0/Cmax (ng/mL) 28.883 35.818   2.490   1.778 
AUC 0-∞  (ng.h/mL) 25.220 27.395 14.437 17.055 
Vd (L/kg)   3.204   1.772   5.367   4.980 
ClB (L/h/kg)   3.188   1.477   2.998   1.378 
F (%) – – 54.454 20.091 
Kel, elimination rate constant; T½el, elimination half-life; Kabs, absorption rate constant; T½ abs,  
absorption  half life; Tmax, time of peak concentration; C0, concentration at zero time; Cmax, peak 
concentration; AUC0-∞ , area under the plasma concentration vs. time curve from 0 to ∞ ; Vd, vo-
lume of distribution (corrected by F); ClB, body clearance (corrected by F) ; F,  bioavailability. 
 
 
Fig. 1. Plasma concentration of butorphanol (mean ± SD; n= 6) vs. time after intravenous and intra-
nasal administration at a dose rate of 0.05 mg/kg to horses. 
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ported by other authors (Sellon et al., 
2009; Knych et al., 2013; Chiavaccini et 
al., 2015). Elimination was rapid, with a 
body clearance of 3.19±1.48 L/h/kg. The 
rapid elimination was also reflected by the 
short half-life (0.681±0.169 h). The esti-
mated clearance was higher than those 
reported for other authors (Sellon et al., 
2009; Chiavaccini et al., 2015). It is diffi-
cult to explain the differences observed 
between previous studies and the present 
study. One explanation is related to the 
polymorphism in CYP2D50 (Corado et 
al., 2016), the cytochrome involved in the 
metabolism of most opioids; in humans 
the high polymorphism of CYP2D6, the 
orthologue to equine CYP2D50, leads to 
ultrarapid metabolisers (St Sauver et al., 
2017), as in this study. Unfortunately, 
there are no comprehensive data on butor-
phanol metabolism in horses.   
Absorption after IN administration, 
was relatively rapid  (T½ abs: 0.426± 
0.320 h) with a bioavailability of 54.45± 
20.09%. This is lower than the value re-
ported after SC (87%) (Chiavaccini et al., 
2015), but higher than after IM admini-
stration (37.3±6.1%) (Sellon et al., 2009). 
It is important to highlight that in the pre-
sent study blood was sampled in the ex-
ternal jugular vein and blood perfusing the 
nasal cavity drains in that same vein. It is 
therefore likely that the samples were not 
adequately mixed and bioavailability may 
be an overestimation of the actual sys-
temic availability (Hedges et al., 2013). 
Maximum observed concentration (Cmax) 
was 2.49±1.78 ng/mL with a Tmax of 
1.48±0.76 h. The Vd, corrected for bio-
availability, was 5.36±4.98 L/kg, the im-
portant intersubject variability reflects the 
high value observed in two equines. The 
ClB, corrected for bioavailability, was 
very similar to that estimated after intra-
venous administration (2.99±1.37 L/h/kg), 
reflecting the rapid elimination of the 
molecule. Elimination half-life was 
1.79±1.42 h. None of the estimated phar-
macokinetic parameters was statistically 
different from the IV route.  
The intranasal administration in horses 
is practical, not stressful and well toler-
ated (Ferreira et al., 2015) besides allows 
bypassing the blood-brain barrier  (Dhuria 
et al., 2010) by different pathways  (Dju-
pesland et al., 2014), all of them related to 
the olfactory function. Considering that 
horses communicate through odours, it is 
expected that CNS-acting drugs suffer 
important transport from the nose to the 
CNS, transforming the IN route in a valu-
able therapeutic alternative.  
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